Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Cabozantinib (Primary) ; Lenvatinib (Primary)
- Indications Neuroendocrine tumours; Paraganglioma; Pheochromocytoma; Thyroid cancer
- Focus Adverse reactions
- 04 Apr 2017 Results (n=17) assessing effect of cabozantinib or lenvatinib on body composition in endocrine tumor patients, presented at The 99th Annual Meeting of the Endocrine Society.
- 16 Nov 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov. record.
- 16 Nov 2015 Planned primary completion date changed from 1 Jan 2019 to 1 Nov 2018 as per NCT.